Leukotriene B4 and Tumor Necrosis Factor Production after invitro Exposure of Rat Alveolar Macrophages to Mineral Dust: Potential Role in Fibrogenesis

  • C. Dubois
  • E. Bissonnette
  • M. Rola-Pleszczynski
Conference paper
Part of the NATO ASI Series book series (volume 30)


Prolonged inhalation of asbestos fibers and silica particles causes chronic inflammatory reactions and interstitial fibrosis. Although the exact mechanism by which these particles can induce lung diseases remains poorly understood, increasing evidence suggests that alveolar macrophages (AM) play a crucial role in the onset and development of asbestosis and silicosis through their ability to release potent inflammatory and fibrogenic mediators (Thomas and Hunninghake, 1987). Activated macrophages produce growth stimulatory activities toward fibroblasts and well characterized cytokines such as tumor necrosis factor (TNF) (Lemaire and al. 1986; Sayers and al. 1987). This cytokine, initially recognized because of its cytotoxic and anti-tumor properties, was shown in recent years to exert a role in systemic and lung inflammation (Moldawer and al. 1987; Bagby and Summer 1988), and in fibroblast growth regulation (Sugarman and al. 1985). Pulmonary macrophages also represent equally a particularly rich source of leukotriene B4 (LTB4). This lipoxygenase product may amplify the inflammatory process partly by its ability to modulate the production of immune and inflammatory cytokines, such as interleukin 1, interleukin 2 and gamma-interferon (Rola-Pleszczynski and Lemaire 1985; Rola-Pleszczynski and al. 1986). In this report, we investigated the role of LTB4 as a potential mediator of lung disease by examining the effect of endogenous and exogenous LTB4 on the regulation of mineral dust-induced INF release by rat AM. The contribution of TNF in macrophage-derived fibrogenic activity was also examined.


Alveolar Macrophage Silica Particle Mineral Dust Asbestos Fiber Lipoxygenase Inhibitor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Bagby G, Summer W (1988) Intratracheal lipopolysaccharide elicits tumor necrosis factor activity in bronchoalveolar lavage luid. Am Rev Respir Dis 137: 43Google Scholar
  2. Klebanoff SJ, Vadas MA, Harlan JM, Sparks IH, Gamble JR, Agosti JM, Watersdorph AM (1986) Stimulation of neutrophils by tumor necrosis factor. J Immunol 136: 4220–4225PubMedGoogle Scholar
  3. Lemaire I, Beaudoin H, Dubois C (1986) Cytokine regulation of lung fibroblast proliferation. Am Rev Respir Dis 134: 653–658PubMedGoogle Scholar
  4. Moldawer LL, Gelin J, Schersten T, Lundholm G (1987) Circulating interleukin 1 and tumor necrosis factor during inflammation. Am J Physiol 253: R922–R928PubMedGoogle Scholar
  5. Osaki Y, Ohashi T, Niwa Y (1986) A comparative study on the effects of inhibitors of the lipoxygenase pathway on neutrophil function: inhibitory effects on neutrophil function may not be attributed to inhibition of the lipoxygenase pathway. Biochem Pharmacol 35: 3481–3488CrossRefGoogle Scholar
  6. Rola-Pleszczynski M, Lemaire I (1985) Leukotrienes augment interleukin 1 production by human monocytes. J Immunol 135: 3958–3961PubMedGoogle Scholar
  7. Rola-Pleszczynski M, Chavaillaz P-A, Lemaire I (1986) Stimulation of interleukin 2 and interferon-gainma production by leukotriene B4 and human lymphocyte culture. Prostagl Leukotrienes and Med 23: 207–210CrossRefGoogle Scholar
  8. Roubin R, Elsas PP, Fiers W, Dessein AJ (1987) Recombinant human tumor necrosis factor (rTNF) enhances leukotriene biosynthesis in neutrophils and eosinophils stimulated with the CA2+ ionophore A23187. Clin Exp Immunol 70: 484–490PubMedGoogle Scholar
  9. Ruff MR, Gifford GE (1981) Tumor necrosis factor in Lymphokine Reports, vol 11. Academic Press, NY, 235–272Google Scholar
  10. Sayer TJ, Macher I, Chung J, Kugler E (1987) The production of tumor necrosis factor by mouse bone marrow-derived macrophages in response to bacterial 1 ipopolysaccharide and a chemical synthesized monosaccharide precursor. J Immunol 138: 2935–2949Google Scholar
  11. Schoenberger CI, Hunninghake GW, Kawanami O, Ferrans VJ, Crystal RG (1982) Role of alveolar macrophages in asbestosis: Modulation of neutrophil migration to the lung after acute asbestos exposure. Thorax 37: 803–809PubMedCrossRefGoogle Scholar
  12. Sugarroan BJ, Aggarwal BB, Hass PE, Figari IS, Palladino MA, Shepard HM (1985) Recombinant human tumor necrosis factor alpha: effects on proliferation of normal and transformed cells in vitro. Science 230: 943–945CrossRefGoogle Scholar
  13. Thomas PD, Hunninghake GW (1987) Current concepts of the pathogenesis of sarcoidosis. Am Rev Respir Dis 135: 747–760PubMedGoogle Scholar
  14. Tsujimoto M, Yokota S, Vilcek J, Weissman N (1986) Tumor necrosis factor provokes superoxide anion generation from neutrophils. Biochem Biophys Res Commun 137: 1094–1100PubMedCrossRefGoogle Scholar
  15. Vilcek J, Palombella VJ, Henriksen-De Stefano D, Swenson C, Feinman R, Hirai M, Tsujimoto M (1986) Activity of tumor necrosis factor and its relationship to other polypeptide growth factors. J Exp Med 163: 632–643PubMedCrossRefGoogle Scholar
  16. White JR, Naccache PH, Molski TFP, Borgeat P, Sha’afi RI (1983) Direct demonstration of increased intracellular concentration of free calcium in rabbit and human neutrophils following stimulation by chemotactic factors. Biochem Biophys Res Comm 113: 44–58PubMedCrossRefGoogle Scholar
  17. Yoshimoto T, Yokoyama C, Ochi K, Yamamoto S, Maki Y, Ashida Y, Terao S, Shiraishi M (1982) 2,3,5-trimethyl6-(12-hydroxy-5, 10-dodedecadiynyl)-1, 4-benzoquinone (AA861), A selective inhibitor of the 5-lipoxygenase reaction and the biosynthesis of slow-reacting substance of anaphylaxis. Biochem Biophys Acta 713: 470–473Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1989

Authors and Affiliations

  • C. Dubois
    • 1
  • E. Bissonnette
    • 1
  • M. Rola-Pleszczynski
    • 1
  1. 1.Immunology Division, Faculty of MedicineUniversity of SherbrookeSherbrookeCanada

Personalised recommendations